---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-26-015155"
form_type: "8-K"
ticker: "TLSI"
cik: "0001826667"
company_name: "TriSalus Life Sciences, Inc."
filed_at: "2026-03-05T23:59:59+00:00"
generated_at: "2026-05-15T19:50:06.572547+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# TriSalus Q4 revenue $13.2M (+60% YoY); reaffirms 2026 revenue guidance $60-62M

## Summary
- Full-year 2025 revenue $45.2M (+53% YoY); Q4 gross margin 86.7% vs 85.3% prior year.
- Adjusted EBITDA loss improved to $0.9M in Q4 2025 from $5.7M loss in Q4 2024.
- Net loss attributable to common shareholders FY2025 $69.7M ($1.84 loss per share) vs $33.2M ($1.31) prior year.
- Raised $46M gross proceeds from public offering post-Q4; cash and equivalents $20.4M at Dec 31, 2025.
- Appointed Michael Stansky to board in Feb 2026; launched TriNav XP infusion system.

## SEC filing metadata
- accession: 0001628280-26-015155
- form_type: 8-K
- ticker: TLSI
- cik: 0001826667
- company_name: TriSalus Life Sciences, Inc.
- filed_at: 2026-03-05T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1826667/000162828026015155/0001628280-26-015155-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1826667/000162828026015155/tlsi-20260305.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-26-015155
- JSON: https://secwatch.observer/filing/0001628280-26-015155.json
- Plain text: https://secwatch.observer/filing/0001628280-26-015155.txt

## Key facts
- Earnings Releases
  TriSalus Life Sciences, Inc. reported 2026 results: revenue $60 million to $62 million. Guidance reaffirmed.
  - Period: 2026
  - Revenue: $60 million to $62 million
  - Guidance: reaffirmed
  - Result: guidance update
  source text: Reaffirms 2026 Revenue Guidance of $60-62 million
  evidence_url: https://www.sec.gov/Archives/edgar/data/1826667/000162828026015155/0001628280-26-015155-index.htm
- Earnings Releases
  TriSalus Life Sciences, Inc. reported the year ended December 31, 2025 results: revenue $45.2 million, net income $69.7 million, EPS $1.84.
  - Period: the year ended December 31, 2025
  - Revenue: $45.2 million
  - Net income: $69.7 million
  - EPS: $1.84
  - Result: reported results
  source text: Revenue, all from sales of the TriNav system, was $45.2 million for the year ended December 31, 2025, an increase of 53% compared to the same period in 2024.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1826667/000162828026015155/0001628280-26-015155-index.htm
- Earnings Releases
  TriSalus Life Sciences, Inc. reported the fourth quarter ended December 31, 2025 results: revenue $13.2 million.
  - Period: the fourth quarter ended December 31, 2025
  - Revenue: $13.2 million
  - Result: reported results
  source text: Generated $13.2 million in net sales, a 60% increase year-over-year
  evidence_url: https://www.sec.gov/Archives/edgar/data/1826667/000162828026015155/0001628280-26-015155-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.